The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Open accessAbstract
Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature of a major subset of primary human brain cancers. These mutations occur at a single amino acid residue of the IDH1 active site, resulting in loss of the enzyme's ability to catalyse conversion of isocitrate to alpha-ketoglutarate. However, only a single copy of the gene is mutated in tumours, raising the possibility that the mutations do not result in a simple loss of function. Here we show that cancer-associated IDH1 mutations result in a new ability of the enzyme to catalyse the NADPH-dependent reduction of alpha-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). Structural studies demonstrate that when arginine 132 is mutated to histidine, residues in the active site are shifted to produce structural changes consistent with reduced oxidative decarboxylation of isocitrate and acquisition of the ability to convert alpha-ketoglutarate to 2HG. Excess accumulation of 2HG has been shown to lead to an elevated risk of malignant brain tumours in patients with inborn errors of 2HG metabolism. Similarly, in human malignant gliomas harbouring IDH1 mutations, we find markedly elevated levels of 2HG. These data demonstrate that the IDH1 mutations result in production of the onco-metabolite 2HG, and indicate that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [3]
In the citing paper
“Wild-type IDH1 and IDH2 catalyze the reversible oxidative decarboxylation of isocitrate to alpha-ketoglutarate (αKG) and CO2 (Figure 4a). Cancer associated mutations in IDH1 and IDH2 eliminate this function and confer a neomorphic activity to the enzyme, generating D-2-hydroxyglutarate (D-2HG) via the reduction of αKG (Figure 4b)(Dang et al., 2009; Ward et al., 2010).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Dang et al., 2009
In the citing paper
“cancer-associated IDH1 R132 mutants display a loss-of-function for the use of isocitrate as substrate, with a concomitant gain-of-function for the reduction of α-ketoglutarate to 2HG”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“There is a marked difference in the enzymatic rate of isocitrate-dependent NADPH production by the wild-type proteins and α-ketoglutarate-dependent NADPH consumption by both IDH1 and IDH2 mutants (Figure 2 and Dang et al., 2009).”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“2HG was found to be elevated in IDH1-mutated gliomas”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“The R132H IDH1 mutation observed in gliomas was found to display a gain of function for the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“In the case of IDH1 mutant proteins, it has been reported that a local supply of NADPH and α-ketoglutarate is required to drive 2HG production (Dang et al., 2009).”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“Thus, various tumors, including glioma, secondary glioblastoma, and acute myeloid leukemia (AML), harboring heterozygous point mutations in the active sites of IDH1/2 show dramatic increases in the R-2-HG levels111,113–115.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [111]
In the citing paper
“Although additional studies are needed, ample experimental data support the recognition of R-2-HG, succinate, and fumarate as oncometabolites.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [111]
In the citing paper
“These results suggest that 2HG-and in particular the R-enantiomer produced by IDH1 mutants (Dang et al, 2009)-is probably an ineffective inhibitor of HIF Pro-hydroxylation, and predict that it would be relatively ineffective in inducing HIF1a.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Dang et al, 2009
In the citing paper
“The high concentrations of R-2HG (more than 10 mM) that have been observed in malignant brain tumours and leukaemias (Dang et al, 2009;Gross et al, 2010;Ward et al, 2010), might be sufficient to inhibit even the less-susceptible 2OG oxygenases.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Dang et al, 2009
In the citing paper
“As production of 2HG by IDH mutations is stereospecific (Dang et al, 2009;Ward et al, 2010), the specificity of inhibition by the 2HG enantiomers is relevant to their potential as mediators of oncogenic pathways.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Dang et al, 2009
In the citing paper
“However, they also cause a gain of function comprising catalysis of 2OG to the R-enantiomer of 2-hydroxyglutarate (R-2HG; Dang et al, 2009;Gross et al, 2010;Ward et al, 2010).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Dang et al, 2009
In the citing paper
“Tumor-associated IDH mutations unmask a latent ability of these enzymes to produce the R enantiomer of 2-hydroxyglutarate, which accumulates to low millimolar levels in IDH mutant tumors (Dang et al., 2009; Gross et al., 2010; Ward et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Dang et al., 2009
In the citing paper
“Mutant IDH protein is a competitive inhibitor of hydroxylases, including the TET family of 5mC hydroxylases120–122.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [121]
In the citing paper
“Oncogenic mutations in genes encoding IDH1/2 result in neomorphic enzyme activity that favors reduction of αKG to d-2-hydroxyglutarate (D-2HG) (167, 168).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [167]
In the citing paper
“This mutation alters the enzymatic ability of IDH1, allowing it to convert α-KG to 2-hydroxyglutarate (2-HG) rather than promote normal isocitrate–to–α-KG inter-conversion (78).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [78]
In the citing paper
“The weight of the evidence now suggests that regulation of HIF-1 stability through decreased PHD2 activity is not the primary effect of IDH mutations (Chowdhury et al., 2011; Dang et al., 2009; Jin et al., 2011; Mardis et al., 2009; Metellus et al., 2011; Williams et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Dang et al., 2009
In the citing paper
“IDH1 mutations at R132 are not simply loss-of-function for isocitrate and α-ketoglutarate interconversion, but also acquire a novel reductive activity to convert α-ketoglutarate to 2-hydroxyglutarate (2HG)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Dang et al., 2009
In the citing paper
“a rare metabolite found at only trace amounts in mammalian cells under normal conditions (Dang et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Dang et al., 2009
In the citing paper
“R(-)-2HG (also known as D-2HG) is the exclusive 2HG stereoisomer produced by IDH1 and IDH2 mutants (Dang et al., 2009; Ward et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Dang et al., 2009
In the citing paper
“This suspicion was confirmed by metabolomics: tumor tissue and cell lines expressing mutant IDH1 or IDH2 produced large quantities of a metabolite, (D)-2-hydroxyglutarate (2-HG), that is vanishingly scarce when only the wild-type enzymes were expressed (Dang et al., 2009).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Dang et al., 2009
In the citing paper
“Surprisingly, even large accumulations of 2-HG do not cause wholesale perturbations of metabolite levels in IDH1-mutant tumors (Dang et al., 2009).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Dang et al., 2009
In the citing paper
“These findings therefore suggest that both suppression of RIP3-mediated necroptosis and MLK3-mediated apoptosis by D-2-HG may contribute to IDH-mutant carcinogenesis140,141.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [141]
In the citing paper
“Finally, D-2HG also impairs necroptosis and the small GTPase Cdc42, leading to suppression of mixed lineage kinase 3 (MLK3)-mediated apoptosis140,141.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [141]
In the citing paper
“D-2-HG has also been found to bind the DNA methyltransferase DNMT1, which subsequently represses receptor-interacting protein kinase 3 (RIP3).”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
The CCP4 suite: programs for protein crystallography
Number Collaborative Computational Project (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,317
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Cited by
Sorted by citations
Items 901–1,000 of 1,009
Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas
Tang, X., Wu, J., Ding, C. C., Lu, M., Keenan, M. M., Lin, C., Lin, C.-A., Wang, C. C., George, D. J., Hsu, D. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2328 · Cited by 81
Self-citationIsocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas
Horbinski, C., Kofler, J., Yeaney, G. A., Camelo-Piragua, S. I., Venneti, S., Louis, D. N., Perry, A., MURDOCH, G. H., & Nikiforova, M. N. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00480.x · Cited by 80
Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma
Jalbert, L. E., Elkhaled, A., Phillips, J. J., Neill, E., Williams, A. A., Crane, J. C., Olson, M. P., Molinaro, A. M., Berger, M. S., Kurhanewicz, J. V., et al. (2017) · Scientific Reports · doi:10.1038/srep44792 · Cited by 80
Hou, H., & Tien, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00674-7 · Cited by 86
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer
Rocca, C., Soda, T., Francesco, E. M. D., Fiorillo, M., Moccia, F. D., Viglietto, G., Angelone, T., & Amodio, N. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04498-5 · Cited by 84
Corona, G., Rizzolio, F., Giordano, A., & Toffoli, G. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.24003 · Cited by 79
Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
Rendina, A. R., Pietrak, B., Smallwood, A. M., Zhao, H., Qi, H., Quinn, C. J., Adams, N. D., Concha, N. O., Duraiswami, C., Thrall, S. H., et al. (2013) · Biochemistry · doi:10.1021/bi400514k · Cited by 81
Zhang, W., & Huang, P. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14623 · Cited by 79
Emerging Roles of ATRX in Cancer
Watson, L. A., Goldberg, H. E., & Bérubé, N. G. (2015) · Epigenomics · doi:10.2217/epi.15.82 · Cited by 82
Laurenti, G., & Tennant, D. A. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160099 · Cited by 86
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino, M., Kurz, S. C., Chiriboga, L. A., Serrano, J., Zeck, B., Sen, N., Patel, S. V., Shen, G., Vasudevaraja, V., Tsirigos, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2312 · Cited by 80
Targeting Metabolic Reprogramming in Acute Myeloid Leukemia
Castro, I., Sampaio‐Marques, B., & Ludovico, P. (2019) · Cells · doi:10.3390/cells8090967 · Cited by 79
2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter
Yang, Z., Jiang, B., Wang, Y., Ni, H., Zhang, J., Xia, J., Shi, M., Hung, L.-M., Ruan, J., Mak, T. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.012 · Cited by 78
Molecular signatures classify astrocytic gliomas by IDH1 mutation status
Toedt, G., Barbus, S., Wolter, M., Felsberg, J., Tews, B., Blond, F., Sabel, M., Hofmann, S., Becker, N., Hartmann, C. J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25448 · Cited by 78
Chromatin modifiers and the promise of epigenetic therapy in acute leukemia
Greenblatt, S. M., & Nimer, S. D. (2014) · Leukemia · doi:10.1038/leu.2014.94 · Cited by 83
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds
Wu, F., Jiang, H., Zheng, B., Kogiso, M., Yao, Y., Zhou, C., Li, X., & Song, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00684 · Cited by 78
Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 80
JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
McKenney, A. S., Lau, A. N., Somasundara, A. V. H., Spitzer, B. G., Intlekofer, A. M., Ahn, J., SHANK, K. R., Rapaport, F. T., Patel, M. A., Papalexi, E., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94516 · Cited by 81
Self-citationEmerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy
Zhu, Y., Dean, A. E., Horikoshi, N., Heer, C. D., Spitz, D. R., & Gius, D. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120844 · Cited by 82
Walsby-Tickle, J., Gannon, J. M., Hvinden, I. C., Bardella, C., Abboud, M. I., Nazeer, A., Hauton, D., Pires, E., Cadoux-Hudson, T. A. D., Schofield, C. J., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0957-6 · Cited by 78
Bao, R., Stapor, D. C., & Luke, J. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00787-6 · Cited by 80
Horbinski, C., Kelly, L. M., Nikiforov, Y. E., Durso, M. B., & Nikiforova, M. N. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090228 · Cited by 80
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 80
Autophagy and oxidative stress in gliomas with IDH1 mutations
Gilbert, M. R., Liu, Y., Neltner, J. H., Pu, H., Morris, A. J., Sunkara, M., Pittman, T. A., Kyprianou, N., & Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1194-6 · Cited by 78
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 86
Hlouschek, J., Hansel, C., Jendrossek, V., & Matschke, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00170 · Cited by 82
Normal Hematopoiesis Is a Balancing Act of Self-Renewal and RegenerationPreprint
Olson, O. C., Kang, Y.-A., & Passegue, E. A. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035519 · Cited by 89
Elhammali, A., Ippolito, J. E., Collins, L., Crowley, J., Marasa, J., & Piwnica-Worms, D. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0572 · Cited by 77
Zeng, A., Hu, Q., Liu, Y., Wang, Z., Cui, X., Li, R., Yan, W., & You, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4920 · Cited by 77
Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
Xia, L., Wu, B., Fu, Z., Fěng, F., Qiao, E., Li, Q., Sun, C., & Ge, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4008 · Cited by 80
Metabolic regulation of stem cell function
Burgess, R., Agathocleous, M., & Morrison, S. J. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12247 · Cited by 81
Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells
Pecqueur, C., Oliver, L., Oizel, K., Lalier-Bretaudeau, L., & Vallette, F. M. (2013) · International Journal of Cell Biology · doi:10.1155/2013/805975 · Cited by 83
Gil‐Zamorano, J., Martín‐Hernández, R., Daimiel, L., Richardson, K., Giordano, E., Nicod, N. M., García-Carrasco, B., Soares, S. M. A., Iglesias‐Gutiérrez, E., Lasunción, M. A., et al. (2014) · Journal of Nutrition · doi:10.3945/jn.113.189050 · Cited by 77
Translational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 78
Amoedo, N. D., Obre, E., & Rossignol, R. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.02.005 · Cited by 76
Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas
Eichinger, P., Alberts, E., Delbridge, C., Trebeschi, S., Valentinitsch, A., Bette, S. J., Huber, T. S., Gempt, J., Meyer, B., Schlegel, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13679-4 · Cited by 76
Richelle, A., Chiang, A. W. T., Kuo, C., & Lewis, N. E. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006867 · Cited by 76
A Review of Radiomics and Deep Predictive Modeling in Glioma Characterization
Gore, S. A., Chougule, T., Jagtap, J., Saini, J. S., & Ingalhalikar, M. (2020) · Academic Radiology · doi:10.1016/j.acra.2020.06.016 · Cited by 80
Comba, A., Faisal, S. M., Varela, M. L., Hollon, T. C., Al‐Holou, W. N., Umemura, Y., Núñez, F. J., Motsch, S., Castro, M. G., & Lowenstein, P. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703764 · Cited by 79
Metabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 78
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
Zheng, B., Yao, Y., Liu, Z., Deng, L., Anglin, J. L., Jiang, H., Prasad, B. V. V., & Song, Y. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400036z · Cited by 76
Genetic and epigenetic alterations of myeloproliferative disorders
Feenstra, J. D. M., & Královics, R. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1235-2 · Cited by 81
Liubinas, S. V., D’Abaco, G. M., Moffat, B. A., Gonzales, M. F., Feleppa, F., Nowell, C. J., Gorelik, A., Drummond, K. J., O'Brien, T. J., Kaye, A. H., et al. (2014) · Epilepsia · doi:10.1111/epi.12662 · Cited by 76
Fathi, A. T., Sadrzadeh, H., Comander, A. H., Higgins, M. J., Bardia, A., Perry, A. M., Burke, M. E., Silver, R. M., Matulis, C. R., Straley, K. S., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0417 · Cited by 77
Self-citationMolecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1
Cahill, D. P., Louis, D. N., & Cairncross, J. G. (2015) · CNS Oncology · doi:10.2217/cns.15.32 · Cited by 77
Nagashima, H., Tanaka, K., Sasayama, T., Irino, Y., Sato, N., Takeuchi, Y., Kyotani, K., Mukasa, A., Mizukawa, K., Sakata, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now090 · Cited by 76
Li, H., Chawla, G., Hurlburt, A. J., Sterrett, M. C., Zaslaver, O., Cox, J. E., Karty, J. A., Rosebrock, A. P., Caudy, A. A., & Tennessen, J. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614102114 · Cited by 76
Pinweha, P., Rattanapornsompong, K., Charoensawan, V., & Jitrapakdee, S. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.05.005 · Cited by 75
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
Graham, N. A., Minasyan, A., Lomova, A., Cass, A. A., Balanis, N. G., Friedman, M., Chan, S. T., Zhao, S. R., Delgado, A., Go, J. L., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167159 · Cited by 78
Current State and Future Prospects of Immunotherapy for Glioma
Kamran, N., Alghamri, M. S., Núñez, F. J., Shah, D., Asad, A. S., Candolfi, M., Altshuler, D. B., Lowenstein, P. R., & Castro, M. G. (2018) · Immunotherapy · doi:10.2217/imt-2017-0122 · Cited by 77
IDH3α regulates one-carbon metabolism in glioblastoma
May, J., Kouri, F. M., Hurley, L., Liu, J., Tommasini-Ghelfi, S., Ji, Y., Gao, P., Calvert, A. E., Lee, A., Chandel, N. S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aat0456 · Cited by 76
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
Tao, L., Mohammad, M. A., Milazzo, G., Moreno‐Smith, M., Patel, T. D., Zorman, B., Badachhape, A., Hernandez, B. E., Wolf, A. B., Zeng, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31331-2 · Cited by 75
Emerging Roles of SIRT5 in Metabolism, Cancer, and SARS-CoV-2 Infection
Fabbrizi, E., Fiorentino, F., Carafa, V., Altucci, L., Mai, A., & Rotili, D. (2023) · Cells · doi:10.3390/cells12060852 · Cited by 77
Okita, Y., Narita, Y., Miyakita, Y., Ohno, M., Matsushita, Y., Fukushima, S., Sumi, M., Ichimura, K., Kayama, T., & Shibui, S. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1564 · Cited by 75
Colorectal cancer: epigenetic alterations and their clinical implications
Puccini, A., Berger, M. D., Naseem, M., Tokunaga, R., Battaglin, F., Cao, S., Hanna, D. L., McSkane, M., Soni, S., Zhang, W., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.003 · Cited by 76
TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations: Figure 1
Kim, Y.-H., Pierscianek, D., Mittelbronn, M. G. A., Vital, A., Mariani, L., Hasselblatt, M., & Ohgaki, H. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200133 · Cited by 74
Clinical impact of molecular biomarkers in gliomas
Siegal, T. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.004 · Cited by 76
Sulfur metabolism and its contribution to malignancy
Ward, N. P., & DeNicola, G. M. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.05.001 · Cited by 74
Mitochondrial metabolism as a target for acute myeloid leukemia treatment
Panina, S., Pei, J., & Kirienko, N. V. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00253-w · Cited by 74
Metabolism and the leukemic stem cell
Abdel-Wahab, O. I., & Levine, R. L. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100523 · Cited by 81
Cancer Metabolism: A Modeling Perspective
Ghaffari, P., Mardinoğlu, A., & Nielsen, J. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00382 · Cited by 76
Molecular Testing of Brain Tumor
Park, S., Won, J., Kim, S., Lee, Y., Park, C., Kim, S., & Choi, S.-H. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.03.08 · Cited by 77
Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma
Voon, H. P. J., Udugama, M., Lin, W., Hii, L. L., Law, R. H. P., Steer, D. L., Das, P. P., Mann, J. R., & Wong, L. H. (2018) · Nature Communications · doi:10.1038/s41467-018-05607-5 · Cited by 79
Turcan, Ş., & Cahill, D. P. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1620238 · Cited by 73
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
Ma, R., & Yun, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.068 · Cited by 73
The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway
Han, C., Zheng, J., Sun, L., Yang, H., Cao, Z., Zhang, X., Zheng, L. T., & Zhen, X.-C. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0225-9 · Cited by 75
Banerjee, S., Ghosh, S., Mandal, A., Ghosh, N., & Sil, P. C. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02801-7 · Cited by 74
Takahashi, H., Hase, H., Yoshida, T., Tashiro, J., Hirade, Y., Kitae, K., & Tsujikawa, K. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14051 · Cited by 73
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation
Yanchus, C., Drucker, K. L., Kollmeyer, T. M., Tsai, R., Winick‐Ng, W., Liang, M., Malik, A., Pawling, J., Lorenzo, S. B. D., Ali, A., et al. (2022) · Science · doi:10.1126/science.abj2890 · Cited by 77
Glioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase
Izquierdo-García, J. L., Cai, L. M., Chaumeil, M. M., Eriksson, P., Robinson, A. E., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108289 · Cited by 73
Isocitrate dehydrogenase mutations in leukemia
McKenney, A. S., & Levine, R. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67266 · Cited by 78
Metabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 75
IDH1 and IDH2: Not Your Typical Oncogenes
Reitman, Z. J., Parsons, D. W., & Yan, H. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.024 · Cited by 75
Heavy Metals and Epigenetic Alterations in Brain Tumors
Caffo, M., Caruso, G., Fata, G. L., Barresi, V., Visalli, M., Venza, M., & Venza, I. (2015) · Current Genomics · doi:10.2174/138920291506150106151847 · Cited by 74
Tang, H., Chen, Y., Liu, X., Wang, S., Lv, Y., Wu, D., Wang, Q., Luo, M., & Deng, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9615 · Cited by 73
Chen, J.-Y., Lai, Y.-S., Tsai, H., Kuo, C.-C., Yen, B. L., Yeh, S., Sun, H. S., & Hung, W.-C. (2016) · Scientific Reports · doi:10.1038/srep32428 · Cited by 75
Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond
Teoh, S. T., & Lunt, S. Y. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1406 · Cited by 77
Thust, S. C., Hassanein, S. M. A., Bisdas, S., Rees, J. H., Hyare, H., Maynard, J. A., Brandner, S., Tur, C., Jäger, H. R., Yousry, T. A., et al. (2018) · European Radiology · doi:10.1007/s00330-018-5351-0 · Cited by 73
Zhou, L., Wang, Z., Hu, C., Zhang, C., Kovatcheva‐Datchary, P., Yu, D., Liu, S., Ren, F., Wang, X., Li, Y., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00663 · Cited by 73
The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 75
Mitochondrial dependency in progression of acute myeloid leukemia
Basak, N. P., & Banerjee, S. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.01.006 · Cited by 75
Frontiers in metabolic reconstruction and modeling of plant genomes
Seaver, S. M. D., Henry, C. S., & Hanson, A. D. (2012) · Journal of Experimental Botany · doi:10.1093/jxb/err371 · Cited by 72
Dąbrowski, M. J., & Wojtaś, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143478 · Cited by 73
Xu, H., Sun, Y., You, B., Huang, C., Ye, D., & Chang, C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.014 · Cited by 72
IDH1 mutations induce organelle defects via dysregulated phospholipids
Lita, A., Pliss, A., Kuzmin, A. N., Yamasaki, T., Zhang, L., Dowdy, T., Burks, C., de Val, N., Celiku, O., Ruiz‐Rodado, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20752-6 · Cited by 72
Liquid biopsies to occult brain metastasis
Rehman, A. U., Κhan, P., Maurya, S. K., Siddiqui, J. A., Santamaria‐Barria, J. A., Batra, S. K., & Nasser, M. W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01577-x · Cited by 72
Investigational cancer drugs targeting cell metabolism in clinical development
Sborov, D. W., Haverkos, B. M., & Harris, P. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.960077 · Cited by 72
Cerebral Neoplasms in L-2 Hydroxyglutaric Aciduria: 3 New Cases and Meta-Analysis of Literature Data
Patay, Z. J., Mills, J. C., Löbel, U., Lambert, A., Sablauer, A., & Ellison, D. W. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2869 · Cited by 72
Pediatric gliomas as neurodevelopmental disorders
Baker, S. J., Ellison, D. W., & Gutmann, D. H. (2015) · Glia · doi:10.1002/glia.22945 · Cited by 76
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma
Vartanian, A., Agnihotri, S., Wilson, M. R., Burrell, K. E., Tonge, P. D., Alamsahebpour, A., Jalali, S., Taccone, M. S., Mansouri, S., Golbourn, B. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11680 · Cited by 74
Tumor Metabolism of Malignant Gliomas
Ru, P., Williams, T. M., Chakravarti, A., & Guo, D. (2013) · Cancers · doi:10.3390/cancers5041469 · Cited by 73
Nilsson, A., Haanstra, J. R., Engqvist, M. K. M., Gerding, A., Bakker, B. M., Klingmüller, U., Teusink, B., & Nielsen, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919250117 · Cited by 71
Wick, A., Bähr, O., Schüler, M., Rohrberg, K. S., Chawla, S. P., Jankú, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4256 · Cited by 71
Biology of IDH mutant cholangiocarcinoma
Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 71
Epigenetic dysregulation in glioma
Kondo, Y., Katsushima, K., Ohka, F., Natsume, A., & Shinjo, K. (2014) · Cancer Science · doi:10.1111/cas.12379 · Cited by 73
Slaninová, V., Krafčíková, M., Pérez-Gómez, R., Steffal, P., Trantı́rek, L., Bray, S. J., & Krejčı́, A. (2016) · Open Biology · doi:10.1098/rsob.150155 · Cited by 71
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky, A., Seltzer, M. J., & Riggins, G. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834d816a · Cited by 71
Cancer stem cells: a potential target for cancer therapy
Qiu, H. Y., Fang, X., Luo, Q., & Ouyang, G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1920-4 · Cited by 72
Metabolic signatures of human breast cancer
Mishra, P., & Ambs, S. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.992217 · Cited by 70
Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
Liu, S., Cadoux-Hudson, T. A. D., & Schofield, C. J. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.012 · Cited by 70
Metadata
- Authors
- Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., Marks, K. M., Prins, R. M., Ward, P. S., Yen, K. E., Liau, L. M., Rabinowitz, J. D., Cantley, L. C., Thompson, C. B., Vander Heiden, M. G., & Su, S. M.
- Affiliations
- Agios Pharmaceuticals (United States) (US)
- Princeton University (US)
- University of California, Los Angeles (US)
- Abramson Cancer Center (US)
- Beth Israel Deaconess Medical Center (US)
- ORCID
- Venue
- Nature
- Published
- 2009-11-22
- Volume
- 462
- Issue
- 7274
- Pages
- 739-744
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2818760
- OpenAlex
- W2080452140
- Cited by
- 4,154
- References
- 26
- Citations by year
- 2026: 184 · 2025: 230 · 2024: 250 · 2023: 257 · 2022: 285 · 2021: 315 · 2020: 297 · 2019: 267 · 2018: 280 · 2017: 270 · 2016: 273 · 2015: 245 · 2014: 218 · 2013: 225 · 2012: 218
- FWCI
- 88.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-06-17)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (P01CA104838, R21CA128620, R01CA105463)
- National Institute of Biomedical Imaging and Bioengineering (P30EB009998)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
- Keywords
- IDH1 mutation, 2-hydroxyglutarate, gain-of-function mutations, isocitrate dehydrogenase, high-grade glioma, glioblastoma, oncometabolites, carcinogenesis, brain cancer, enzyme structure, tumor progression
- MeSH terms
- Arginine, Brain Neoplasms, Cell Line, Glioma, Glutarates, Histidine, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Models, Molecular, Mutation, Protein Conformation, Crystallography, X-Ray, Disease Progression, Catalytic Domain, Mutant Proteins, Enzyme Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
